GPC3 and hepatocellular carcinoma: Sorafenib-loaded PEG-PLGA NPs modified with the antibody hGC33 to glypican-3 (GPC3) can effectively target GPC3-positive HCC cells by inhibiting the Wnt pathway, downregulating cyclin D1 expression, inhibiting EMT, and inactivating the RAS and RAF on MAPK signaling pathway [74].